 |
50 Diseases |  |
29 Trials |
|
29 Trials |  |
3299 News |  |
| «12...27282930313233343536373839» |
- ||| Bimzelx (bimekizumab) / UCB, Cimzia (certolizumab pegol) / Astellas, UCB
Clinical: Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 18, 2016
P2, N=102, Recruiting, Sponsor: UCB Celltech
N=180 --> 102 | Trial primary completion date: Jun 2017 --> Dec 2016
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed, Enrollment change: Cimzia Versus Mesalamine for Crohn's Recurrence (clinicaltrials.gov) - Mar 16, 2016
P4, N=10, Active, not recruiting, Sponsor: Milton S. Hershey Medical Center
N=180 --> 102 | Trial primary completion date: Jun 2017 --> Dec 2016 Recruiting --> Active, not recruiting | N=24 --> 10
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: CRIB: A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta (clinicaltrials.gov) - Mar 15, 2016
P1, N=20, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Recruiting --> Active, not recruiting | N=24 --> 10 Trial primary completion date: Apr 2016 --> Nov 2016
- ||| Bimzelx (bimekizumab) / UCB, Cimzia (certolizumab pegol) / Astellas, UCB
Clinical: Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 15, 2016
P2, N=180, Recruiting, Sponsor: UCB Celltech
Trial primary completion date: Apr 2016 --> Nov 2016 N=102 --> 180 | Trial primary completion date: Dec 2016 --> Jun 2017
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date, Combination therapy, Metastases: Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas (clinicaltrials.gov) - Mar 11, 2016
P1, N=34, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=102 --> 180 | Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Apr 2016 --> Apr 2017
- Biomarker, Enrollment change, Trial primary completion date: RA-BioStop: Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis (clinicaltrials.gov) - Feb 26, 2016
P4, N=110, Recruiting, Sponsor: Medical University of Graz
Trial primary completion date: Apr 2016 --> Apr 2017 N=68 --> 110 | Trial primary completion date: Jun 2016 --> Jul 2017
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change, Trial termination, Trial primary completion date: EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment (clinicaltrials.gov) - Feb 21, 2016
P4, N=1, Terminated, Sponsor: Baylor College of Medicine
N=68 --> 110 | Trial primary completion date: Jun 2016 --> Jul 2017 N=20 --> 1 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Mar 2014; Not enough subjects to reach accrual goals.
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion, Trial primary completion date, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-na (clinicaltrials.gov) - Feb 17, 2016
P3, N=880, Completed, Sponsor: UCB Pharma SA
N=20 --> 1 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Mar 2014; Not enough subjects to reach accrual goals. Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Jul 2014
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate (clinicaltrials.gov) - Feb 10, 2016
P4, N=916, Completed, Sponsor: UCB Pharma SA
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Jul 2014 Active, not recruiting --> Completed
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 30, 2016
P3, N=100, Active, not recruiting, Sponsor: Korea Otsuka Pharmaceutical Co.,Ltd.
Active, not recruiting --> Completed Trial primary completion date: Oct 2015 --> Jun 2016
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: RAPID-C: A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jan 20, 2016
P3, N=431, Active, not recruiting, Sponsor: UCB Pharma SA, Belgium
Trial primary completion date: Oct 2015 --> Jun 2016 Recruiting --> Active, not recruiting
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: CRADLE: A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia (clinicaltrials.gov) - Jan 20, 2016
P1, N=17, Completed, Sponsor: UCB BIOSCIENCES, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment open: MAZERATI: Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept (clinicaltrials.gov) - Jan 15, 2016
P4, N=90, Recruiting, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: CIMPACT: Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) (clinicaltrials.gov) - Jan 15, 2016
P3, N=559, Active, not recruiting, Sponsor: UCB Biopharma S.P.R.L.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open, Trial initiation date: Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis (clinicaltrials.gov) - Dec 14, 2015
P3, N=30, Recruiting, Sponsor: ICStudy, LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Jul 2015 --> Dec 2015
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: CRADLE: A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia (clinicaltrials.gov) - Dec 5, 2015
P1, N=17, Active, not recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Not yet recruiting --> Recruiting | Initiation date: Jul 2015 --> Dec 2015 Recruiting --> Active, not recruiting
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment status: RAPID-C OLE: An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044 (clinicaltrials.gov) - Dec 5, 2015
P3, N=320, Enrolling by invitation, Sponsor: UCB Pharma SA
Recruiting --> Active, not recruiting Recruiting --> Enrolling by invitation
- Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: NORD-STAR: Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction (clinicaltrials.gov) - Dec 5, 2015
P4, N=800, Recruiting, Sponsor: Karolinska Institutet
Recruiting --> Enrolling by invitation Trial primary completion date: Dec 2018 --> Dec 2020
- Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity (clinicaltrials.gov) - Dec 3, 2015
P4, N=500, Recruiting, Sponsor: Karolinska Institutet
Trial primary completion date: Dec 2018 --> Dec 2020 Trial primary completion date: Dec 2018 --> Dec 2020
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open: IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA (clinicaltrials.gov) - Dec 3, 2015
P4, N=200, Recruiting, Sponsor: University of Illinois at Chicago
Trial primary completion date: Dec 2018 --> Dec 2020 Not yet recruiting --> Recruiting
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
New trial: Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease (clinicaltrials.gov) - Dec 2, 2015
P=N/A, N=90, Recruiting, Sponsor: University of Maryland
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
New trial: THERAPIST: Th17 Responses Evaluated in RA Patients on Inhibitors of TNF? (clinicaltrials.gov) - Dec 2, 2015
P=N/A, N=50, Recruiting, Sponsor: Queen Mary University of London
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: CIMPASI-1: An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (clinicaltrials.gov) - Nov 30, 2015
P3, N=225, Active, not recruiting, Sponsor: UCB Biopharma S.P.R.L.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Nov 15, 2015
P=N/A, N=1360, Recruiting, Sponsor: UCB Pharma SA
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2018 --> Nov 2019
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change, Trial termination, Trial primary completion date: Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD) (clinicaltrials.gov) - Nov 11, 2015
P=N/A, N=199, Terminated, Sponsor: UCB Pharma
Activities covering the whole Russian Federation. Primary objectives could not be met due to critical missing information.
- | Cimzia (certolizumab pegol) / Astellas, UCB
New P4 trial: APOLLO: Does Clinical Response Correlate With Serum Certolizumab Levels? (clinicaltrials.gov) - Nov 6, 2015
P4, N=20, Not yet recruiting, Sponsor: Shafran Gastroenterology Center
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: RAPID-C OLE: An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044 (clinicaltrials.gov) - Oct 26, 2015
P3, N=320, Recruiting, Sponsor: UCB Pharma SA
Primary objectives could not be met due to critical missing information. Trial primary completion date: May 2016 --> Nov 2016
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial: Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870 (clinicaltrials.gov) - Oct 26, 2015
P3, N=86, Completed, Sponsor: Astellas Pharma Inc
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: CIMPASI-2: A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (clinicaltrials.gov) - Oct 16, 2015
P3, N=225, Active, not recruiting, Sponsor: UCB Biopharma S.P.R.L.
Trial primary completion date: May 2016 --> Nov 2016 Recruiting --> Active, not recruiting
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-na (clinicaltrials.gov) - Sep 25, 2015
P3, N=880, Completed, Sponsor: UCB Pharma
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: CIMAX: A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=678, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
Active, not recruiting --> Completed Trial primary completion date: Jan 2018 --> Oct 2017
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: CRIB: A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta (clinicaltrials.gov) - Sep 24, 2015
P1, N=20, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Trial primary completion date: Jan 2018 --> Oct 2017 Trial primary completion date: Oct 2015 --> Feb 2016
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial: C-AXSPAND: Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS (clinicaltrials.gov) - Sep 17, 2015
P3, N=300, Recruiting, Sponsor: UCB BIOSCIENCES GmbH
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: RAPID-PsA: Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis (clinicaltrials.gov) - Sep 14, 2015
P3, N=409, Completed, Sponsor: UCB BIOSCIENCES GmbH
Trial primary completion date: Oct 2015 --> Feb 2016 Active, not recruiting --> Completed
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: RAPID-axSpA: Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (clinicaltrials.gov) - Sep 14, 2015
P3, N=325, Completed, Sponsor: UCB BIOSCIENCES GmbH
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open, Enrollment change, Trial primary completion date: NIMRA: Novel Imaging Markers for Rheumatoid Arthritis (clinicaltrials.gov) - Aug 31, 2015
P4, N=40, Enrolling by invitation, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Enrolling by invitation | N=20 --> 40 | Trial primary completion date: Feb 2015 --> May 2017
- |||||| Cimzia (certolizumab pegol) / Astellas, UCB
Clinical: C-OPTIMISE: Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo (clinicaltrials.gov) - Aug 20, 2015
P3, N=750, Recruiting, Sponsor: UCB BIOSCIENCES GmbH
Active, not recruiting --> Enrolling by invitation | N=20 --> 40 | Trial primary completion date: Feb 2015 --> May 2017 Not yet recruiting --> Recruiting
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: A Study of Certolizumab Pegol to Evaluate Pharmacokinetics and Safety in Adult Healthy Chinese Subjects (clinicaltrials.gov) - Aug 14, 2015
P1, N=36, Completed, Sponsor: UCB Pharma SA
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: Pediatric Arthritis Study of Certolizumab Pegol (clinicaltrials.gov) - Aug 12, 2015
P3, N=163, Active, not recruiting, Sponsor: UCB BIOSCIENCES GmbH
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial: C-OPTIMISE: Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo (clinicaltrials.gov) - Jul 22, 2015
P3, N=750, Not yet recruiting, Sponsor: UCB BIOSCIENCES GmbH
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Biomarker, Trial completion: Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis (clinicaltrials.gov) - Jul 22, 2015
P3, N=316, Completed, Sponsor: Astellas Pharma Inc
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: A Study of Certolizumab Pegol to Evaluate Pharmacokinetics and Safety in Adult Healthy Chinese Subjects (clinicaltrials.gov) - Jul 17, 2015
P1, N=36, Active, not recruiting, Sponsor: UCB Pharma SA
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial: Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis (clinicaltrials.gov) - Jul 15, 2015
P3, N=30, Not yet recruiting, Sponsor: ICStudy, LLC
- Enrollment open, Trial initiation date, Surgery: Anti-TNF? Use During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 8, 2015
P4, N=660, Recruiting, Sponsor: Centre Hospitalier Universitaire de Qu
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Oct 2014 --> Jul 2015
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion, Combination therapy: SPEED: Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 11, 2015
P4, N=132, Completed, Sponsor: UCB Italy s.p.a.
Not yet recruiting --> Recruiting | Initiation date: Oct 2014 --> Jul 2015 Active, not recruiting --> Completed
- | Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
New P4 trial: Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity (clinicaltrials.gov) - Jun 9, 2015
P4, N=500, Recruiting, Sponsor: Karolinska Institutet
- Orencia (abatacept) / BMS, Rituxan (rituximab) / Roche
Enrollment closed: SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. (clinicaltrials.gov) - May 28, 2015
P4, N=477, Active, not recruiting, Sponsor: Julia Brown
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Cimzia (certolizumab pegol) / Astellas, UCB
New P4 trial: IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA (clinicaltrials.gov) - May 22, 2015
P4, N=200, Not yet recruiting, Sponsor: University of Illinois at Chicago
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: CRIB: A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta (clinicaltrials.gov) - May 1, 2015
P1, N=20, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2015 --> Oct 2015
- ||||| Bimzelx (bimekizumab) / UCB, Cimzia (certolizumab pegol) / Astellas, UCB
Clinical: Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Apr 30, 2015
P2, N=102, Recruiting, Sponsor: UCB Celltech